Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Systematic Review and Meta-Analysis

Free Access

Postnatal Hydrocortisone for Preventing or Treating Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review

Doyle L.W.a · Ehrenkranz R.A.b · Halliday H.L.c

Author affiliations

aDepartments of Obstetrics and Gynaecology, and Paediatrics, University of Melbourne, Royal Women’s Hospital, and Murdoch Children’s Research Institute, Parkville, Vic., Australia; bDepartment of Pediatrics, Yale University School of Medicine, New Haven, Conn., USA; cDepartment of Child Health, Queen’s University Belfast, and Perinatal Medicine, Royal Jubilee Maternity Service, Belfast, UK

Corresponding Author

Prof. Lex W. Doyle

Department of Obstetrics and Gynaecology, The Royal Women’s Hospital

20 Flemington Rd

Parkville, Vic. 3052 (Australia)

Tel. +61 3 8345 3716, Fax +61 3 8345 3702, E-Mail lwd@unimelb.edu.au

Related Articles for ""

Neonatology 2010;98:111–117

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Corticosteroids have been used widely after birth in preterm infants with respiratory failure; hydrocortisone may be preferable to other corticosteroids for this purpose. Objectives: To determine if postnatal hydrocortisone is useful to prevent or treat bronchopulmonary dysplasia (BPD) in preterm infants. Methods: Randomised controlled trials (RCTs) of postnatal hydrocortisone therapy to prevent or treat BPD were sought. Data regarding clinical outcomes including mortality, BPD, death or BPD, complications during the primary hospitalisation, and long-term outcome were abstracted and analysed using RevMan 5. Results: Eight RCTs enrolling a total of 880 participants were eligible. In all trials treatment was started in the first week of life; there were no trials of treatment started in infants who were chronically ventilator-dependent after the first week of life with established or evolving BPD. A meta-analysis of the available trials demonstrated little evidence for a direct effect of hydrocortisone on the rates of BPD, mortality, or the combined outcome of BPD or mortality. Hydrocortisone in the doses used in these eight studies had few beneficial or harmful effects; the notable exception was an increase in gastrointestinal perforation. Conclusions: Postnatal hydrocortisone in the doses and regimens used in the reported trials has few beneficial or harmful effects and cannot be recommended for prevention of BPD. There are no randomised trials to substantiate the use of hydrocortisone in chronically ventilator-dependent infants with established or evolving BPD.

© 2010 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Systematic Review and Meta-Analysis

Published online: February 12, 2010
Issue release date: August 2010

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)

For additional information: http://www.karger.com/NEO

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.